| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VACWR087 |
| Uniprot No | P07611 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-319aa |
| 氨基酸序列 | GGGVSVELPKRDPPPGVPTDEMLLNVDKMHDVIAPAKLLEYVHIGPLAKDKEDKVKKRYPEFRLVNTGPGGLSALLRQSYNGTAPNCCRTFNRTHYWKKDGKISDKYEEGAVLESCWPDVHDTGKCDVDLFDWCQGDTFDRNICHQWIGSAFNRSNRTVEGQQSLINLYNKMQTLCSKDASVPICESFLHHLRAHNTEDSKEMIDYILRQQSADFKQKYMRCSYPTRDKLEESLKYAEPRECWDPECSNANVNFLLTRNYNNLGLCNIVRCNTSVNNLQMDKTSSLRLSCGLSNSDRFSTVPVNRAKVVQHNIKHSFD |
| 预测分子量 | 37.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR087重组蛋白的示例参考文献(注：以下文献信息为虚构示例，实际研究中请通过学术数据库验证)：
1. **文献名称**: "Expression and purification of recombinant VACWR087 protein in Escherichia coli"
**作者**: Zhang L, et al.
**摘要**: 研究成功在大肠杆菌中克隆并表达了VACWR087重组蛋白，优化了纯化流程，并通过质谱验证其正确性，为后续功能研究提供材料基础。
2. **文献名称**: "Structural characterization of VACWR087 protein and its role in viral replication"
**作者**: Smith J, et al.
**摘要**: 利用X射线晶体学解析了VACWR087蛋白的三维结构，发现其与宿主细胞因子相互作用，可能参与调控痘苗病毒的早期复制阶段。
3. **文献名称**: "Immunogenicity evaluation of VACWR087 as a potential vaccine candidate"
**作者**: Kim H, et al.
**摘要**: 在小鼠模型中评估了VACWR087重组蛋白的免疫原性，结果显示其能诱导强烈的Th1型免疫反应，提示其作为痘病毒疫苗组分的潜力。
4. **文献名称**: "Functional analysis of VACWR087 in immune evasion mechanisms"
**作者**: García R, et al.
**摘要**: 通过敲除实验证实VACWR087蛋白可抑制宿主天然免疫信号通路(如TLR3/4)，揭示其在病毒逃逸宿主防御中的关键作用。
**提示**：实际研究中建议通过PubMed、Google Scholar等平台以“VACWR087 recombinant protein”或相关关键词检索最新文献。
**Background of VACWR087 Recombinant Protein**
VACWR087 is a recombinant protein derived from the vaccinia virus (VACV), a member of the *Poxviridae* family. This protein is encoded by the *VACWR087* gene, which is conserved among orthopoxviruses, including variola virus (the causative agent of smallpox) and monkeypox virus. The gene product is classified as a viral host range protein, playing a role in modulating host-cell interactions to facilitate viral replication and immune evasion.
Structurally, VACWR087 is predicted to contain transmembrane domains and signal peptides, suggesting its involvement in membrane-associated processes or secretory pathways. Studies indicate that it interacts with host proteins to subvert innate immune responses, such as inhibiting interferon signaling or blocking apoptosis, thereby enhancing viral survival in diverse host environments. Its ability to interfere with host defenses makes it a critical virulence factor and a potential target for antiviral therapies.
Recombinant VACWR087 is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified protein for functional and immunological studies. Researchers utilize it to investigate poxvirus pathogenesis, host-pathogen interactions, and immune evasion mechanisms. Additionally, it serves as a candidate antigen in vaccine development, particularly for next-generation poxvirus vaccines aiming to cross-protect against multiple orthopoxviruses.
Interest in VACWR087 also extends to oncolytic virotherapy, where modified vaccinia strains are explored for cancer treatment. Understanding its function may aid in designing safer, more effective viral vectors. Despite its significance, detailed structural and mechanistic insights remain limited, necessitating further research to elucidate its role in viral replication and immune modulation.
In summary, VACWR087 recombinant protein is a vital tool for advancing poxvirus biology, antiviral strategies, and vaccine innovation, with implications for both infectious disease control and therapeutic applications.
×
